These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 21263005)

  • 21. Isointegral body surface maps and left ventricular hypertrophy in post-infarction heart failure patients.
    Mozos I; Hancu M; Jost N
    Acta Physiol Hung; 2012 Mar; 99(1):18-24. PubMed ID: 22425804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High salt intake accelerated cardiac remodeling in spontaneously hypertensive rats: time window of left ventricular functional transition and its relation to salt-loading doses.
    Gao F; Han ZQ; Zhou X; Shi R; Dong Y; Jiang TM; Li YM
    Clin Exp Hypertens; 2011; 33(7):492-9. PubMed ID: 21529316
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between long-term prescription of febuxostat and the progression of heart failure with preserved ejection fraction in patients with hypertension and asymptomatic hyperuricemia.
    Pan JA; Lin H; Wang CQ; Zhang JF; Gu J
    Heart Vessels; 2020 Oct; 35(10):1446-1453. PubMed ID: 32430700
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Different patterns of the left ventricle of heart in hypertensive patients].
    Wen D; Huang L; Wang J
    Hunan Yi Ke Da Xue Xue Bao; 2003 Dec; 28(6):623-6. PubMed ID: 15804076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pressure overload hypertrophy and congestive heart failure. Where is the "Achilles' heel"?
    Peterson KL
    J Am Coll Cardiol; 2002 Feb; 39(4):672-5. PubMed ID: 11849867
    [No Abstract]   [Full Text] [Related]  

  • 26. Macrophages dictate the progression and manifestation of hypertensive heart disease.
    Kain D; Amit U; Yagil C; Landa N; Naftali-Shani N; Molotski N; Aviv V; Feinberg MS; Goitein O; Kushnir T; Konen E; Epstein FH; Yagil Y; Leor J
    Int J Cardiol; 2016 Jan; 203():381-95. PubMed ID: 26539962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of left ventricular systolic function using midwall mechanics in patients >60 years of age with hypertensive heart disease and heart failure.
    Vinch CS; Aurigemma GP; Simon HU; Hill JC; Tighe DA; Meyer TE
    Am J Cardiol; 2005 Nov; 96(9):1299-303. PubMed ID: 16253602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study.
    Roman MJ; Okin PM; Kizer JR; Lee ET; Howard BV; Devereux RB
    J Hypertens; 2010 Feb; 28(2):384-8. PubMed ID: 20051906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Apoptosis in hypertensive heart disease.
    Díez J; Fortuño MA; Ravassa S
    Curr Opin Cardiol; 1998 Sep; 13(5):317-25. PubMed ID: 9823788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The transition from hypertrophy to failure: how certain are we?
    Drazner MH
    Circulation; 2005 Aug; 112(7):936-8. PubMed ID: 16103249
    [No Abstract]   [Full Text] [Related]  

  • 31. Hypertension and heart failure: a dysfunction of systole, diastole or both?
    Yip GW; Fung JW; Tan YT; Sanderson JE
    J Hum Hypertens; 2009 May; 23(5):295-306. PubMed ID: 19037230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multifaceted approach to analyzing the pathogenesis of cardiovascular disease.
    Sano M
    Circ J; 2012; 76(11):2521-9. PubMed ID: 23037324
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myocardial reverse remodeling: how far can we rewind?
    Rodrigues PG; Leite-Moreira AF; Falcão-Pires I
    Am J Physiol Heart Circ Physiol; 2016 Jun; 310(11):H1402-22. PubMed ID: 26993225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Left ventricular hypertrophy: beyond the image and defining the human cardiac phenotype in hypertension.
    Jennings GL; McMullen JR
    J Hypertens; 2007 May; 25(5):941-7. PubMed ID: 17414655
    [No Abstract]   [Full Text] [Related]  

  • 35. Relative role of left ventricular geometric remodeling and of morphological and functional myocardial remodeling in the transition from compensated hypertrophy to heart failure in rats with supravalvar aortic stenosis.
    Bregagnollo EA; Mestrinel MA; Okoshi K; Carvalho FC; Bregagnollo IF; Padovani CR; Cicogna AC
    Arq Bras Cardiol; 2007 Feb; 88(2):225-33. PubMed ID: 17384842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beta-adrenergic activation initiates chamber dilatation in concentric hypertrophy.
    Badenhorst D; Veliotes D; Maseko M; Tsotetsi OJ; Brooksbank R; Naidoo A; Woodiwiss AJ; Norton GR
    Hypertension; 2003 Mar; 41(3):499-504. PubMed ID: 12623950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of diastolic properties in the transition to failure in a mouse model of the cardiac dilatation.
    Costandi PN; Frank LR; McCulloch AD; Omens JH
    Am J Physiol Heart Circ Physiol; 2006 Dec; 291(6):H2971-9. PubMed ID: 16861693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Heart failure--are there gender aspects?].
    Regitz-Zagrosek V; Lehmkuhl E; Lehmkuhl HB
    Internist (Berl); 2008 Apr; 49(4):422-6, 428. PubMed ID: 18301870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress.
    Kandalam V; Basu R; Moore L; Fan D; Wang X; Jaworski DM; Oudit GY; Kassiri Z
    Circulation; 2011 Nov; 124(19):2094-105. PubMed ID: 21986284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hypertensive heart disease: the definition of subgroups using left ventricular mass, the shortening fraction and the E/A ratio as parameters].
    Coucelo JA; Coucelo J; do Valle J
    Rev Port Cardiol; 1995 Oct; 14(10):761-2. PubMed ID: 7492413
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.